Hyperkalemia is a significant risk of medications that slow progression of chronic kidney disease. Oftentimes these medications or their optimal doses are avoided as a means to mitigate the risk of hyperkalemia, withholding the full potential benefit for our patients. Complicating this problem is the reality that evidence-based guidelines for managing hyperkalemia in patients with chronic kidney disease are sparse.
Dr. Meaney is a clinical associate professor at the University at Buffalo School of Pharmacy and Pharmaceutical Sciences. He specializes in nephrology pharmacy. His practice involves acute care nephrology and internal medicine. Dr. Meaney's research team focuses on optimizing pharmacologic management of anemia in CKD.
In Part 5, we will present strategies to overcome the barriers presented in Part 1-4. These strategies include: multidisciplinary team-based care that can provide comprehensive medication management, or CMM; overcoming barriers to access medications; using a shared decision making, patient-centered model of care; and patient / caregiver tools to improve medication use.